Abstract 89P
Background
Current treatment strategies have improved gastric cancer (GC) patient survival yet disease progression risks remain considerable. Attention is directed to immune homeostasis mediators as indicators of therapy impact. Study aimed at investigating immunomodulatory cells & cytokines profiles in chemotherapy-naïve and Neoadjuvant chemotherapy (NACT) treated GC patients.
Methods
Prospective cohorts of 46 GC patients scheduled for surgical tumor excision first (CTn; n=18) or following NACT treatment (NACT; n=28) were included. NACT were grouped according to Mandard’s criteria into Responders (R;TRG1- 3;n=14) and Non-Responders(NR;TRG4-5;n=14). Peripheral blood samples for PBMCs and serum isolation were collected before surgery. Characterization of immune populations (cytotoxic CD3+CD8+ T-cells, CD4+FOXP3+ T-regs, CD3- CD16+CD56mid+ NKcells, CD3+CD16+ NKTcells & CD14+CD16-/CD14+CD16+/CD14-CD16+monocytes) & serum cytokines (IL-2, IL-4, IL-6, IL- 10, TNFa, IL-17a; by Cytometric Bead Arrays) was performed with FACS.
Results
NACT patient profiles revealed immune status differences between R and NR patients. R were defined by upregulated Tregs (p=0.016 vs NR), antitumor NKcells and intermediate (CD14+CD16+) monocytes (p=0.031 vs NR) and a concomitant profile of moderate increase of cytokines IL2, IL4, IL6 and IL10. In contrast, NR were characterized by increased classical (CD14+CD16-) monocytes, cytotoxic Tcells and NKTcells. NR also showed a reduction of IL2 and anti-inflammatory cytokines IL10 and IL4. CTn patients exhibited a similar to NR immunoprofile of increased cytotoxic populations, but also relatively increased Tregs, whilst cytokine patterns revealed predominance of pro- inflammatory TNFa and elevated IL4 and IL17a.
Conclusions
Responders were characterized by abundance of contributing to immunocompetence immune cells & antitumor acting cytokines whilst tumour progression in CTn & chemoresistant patients correlated with predominance of cytotoxic immunosurveilance populations & deprivation of immunoregulatory cytokines. Evidence highlights the immunomodulators profilling potential towards personalizing GC patient management.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
National and Kapodistrian University of Athens, Greece.
Funding
ERAPerMed 2019-275 (GRAMMY). ERAPerMed - Joint Transnational Call for Proposals (2019) for “Personalised Medicine: Multidisciplinary Research Towards Implementation”.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
146P - The prognosis value of heat-shock proteins in esophagogastric cancer: A systematic review and meta-analysis
Presenter: Eric Nakamura
Session: Cocktail & Poster Display session
Resources:
Abstract
148P - Identification of potential predictive biomarkers for ovarian cancer chemotherapy response
Presenter: Alsina Nurgalieva
Session: Cocktail & Poster Display session
Resources:
Abstract
149P - Rare RAS mutations are associated with recurrence patterns and recurrence-free survival in colon cancer: First results from Morocco
Presenter: Fatima Agy
Session: Cocktail & Poster Display session
Resources:
Abstract
151P - Development of a predictive model for response to neoadjuvant chemoradiation therapy of rectal cancer using the immunologic profile
Presenter: Eun Shin
Session: Cocktail & Poster Display session
Resources:
Abstract
152P - Biomarkers of neoadjuvant chemoradiotherapy response in locally advanced rectal cancer
Presenter: Cibele Masotti
Session: Cocktail & Poster Display session
Resources:
Abstract
153P - BRAF variants and therapy outcomes in melanoma
Presenter: Eftychia Chatziioannou
Session: Cocktail & Poster Display session
Resources:
Abstract
154P - The impact of proton pump inhibitors in the prognosis of patients with non-metastatic nasopharyngeal carcinoma
Presenter: João Barbosa Martins
Session: Cocktail & Poster Display session
Resources:
Abstract
155P - Use of machine learning for the identification of molecular biomarkers to predict response to neoadjuvant chemotherapy in locally advanced breast cancer patients
Presenter: María Del Río Pisula
Session: Cocktail & Poster Display session
Resources:
Abstract
156P - Molecularly driven therapy recommended by a molecular tumor board: Accessible option or privilege for a minority of patients? A single-center experience from the Czech Republic
Presenter: Michal Eid
Session: Cocktail & Poster Display session
Resources:
Abstract
157P - PCM4EU academy: An educational program for precision oncology
Presenter: Loic Verlingue
Session: Cocktail & Poster Display session
Resources:
Abstract